Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammed Ogaily

Medical Oncology Brownstown Twp, MI Medical Doctor

NPI 1740279173 CMS profile 305461

19727 Allen Rd Ste 12, Brownstown Twp, MI 48183

Open in the dashboard

General payments

$10,125

451 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammed Ogaily of Brownstown Twp, MI is reported in the CMS Open Payments database as having received $10,125 across 451 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,969 81
2024 General $2,331 112
2023 General $2,254 87
2022 General $1,856 81
2021 General $1,180 58
2020 General $209 13
2019 General $327 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammed Ogaily
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Mohammed Ogaily were reported at $1,969. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Mohammed Ogaily Medical Oncology median Middle half National median
2019 $327 $968 $140–$6,658 $163
2020 $209 $747 $102–$5,891 $114
2021 $1,180 $430 $50–$4,098 $132
2022 $1,856 $812 $127–$4,907 $149
2023 $2,254 $957 $144–$5,248 $160
2024 $2,331 $1,042 $149–$5,650 $164
2025 $1,969 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,140 39 payments
  2. Genentech USA, Inc. $687 33 payments
  3. Pfizer Inc. $521 31 payments
  4. Exelixis Inc. $395 7 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $392 13 payments
  6. Amgen Inc. $356 18 payments
  7. Daiichi Sankyo Inc. $313 14 payments
  8. Genzyme Corporation $306 13 payments
  9. AstraZeneca Pharmaceuticals LP $300 16 payments
  10. E.R. Squibb & Sons, L.L.C. $285 16 payments
  11. Other $5,430 251 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,050 435 payments
  2. Long term medical supply or device loan $598 6 payments
  3. Education $477 10 payments
Products named General payments · program years 2019–2025
  1. KISQALI $425 9 payments
  2. CABOMETYX $342 4 payments
  3. KEYTRUDA $268 11 payments
  4. TUKYSA $265 14 payments
  5. FOTIVDA $240 7 payments
  6. TECENTRIQ $239 15 payments
  7. XTANDI $238 14 payments
  8. Lenvima $220 10 payments
  9. LIBTAYO $213 9 payments
  10. XARELTO $190 11 payments
  11. Other $9,442 466 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

1,836

Median for Hematology-Oncology: 604

Drug cost

$6,070,784

Median for Hematology-Oncology: $1,306,514

Branded share of claims

36.4%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Revlimid Lenalidomide Brand 76 $1,102,964
Pomalyst Pomalidomide Brand 28 $653,585
Ojjaara Momelotinib Dihydrochloride Brand 18 $506,233
Xtandi Enzalutamide Brand 37 $463,420
Promacta Eltrombopag Olamine Brand 47 $327,318
Brukinsa Zanubrutinib Brand 22 $323,041
Jakafi Ruxolitinib Phosphate Brand 16 $268,819
Kisqali Ribociclib Succinate Brand 14 $235,658
Lynparza Olaparib Brand 13 $216,650
Ibrance Palbociclib Brand 13 $213,045

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 122 billing codes

Paid by Medicare

$2,888,221

Of which drugs: $2,629,385

Medicare patients

606

Average age 75

Services billed

221,716

387 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Cancer 48%
Ischemic heart disease 43%
Diabetes 41%
Chronic kidney disease 37%
COPD 36%
Heart failure 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 59 10,980 $227,835
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg Q5119 Office 11 3,400 $53,216
Injection, ferric carboxymaltose, 1 mg J1439 Office 37 55,500 $48,390
Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 Office 11 4,610 $29,370
Injection, fosaprepitant, 1 mg J1453 Office 28 19,950 $2,228
Injection, palonosetron hcl, 25 mcg J2469 Office 32 1,627 $1,155
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 36 241 $230
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 24 2,296 $202
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 26 120 $77

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 69 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VENCLEXTA
  • AbbVie, Inc. $94
  • Genentech USA, Inc. $79
$173 20 —
ENHERTU
  • Daiichi Sankyo Inc. $45
  • AstraZeneca Pharmaceuticals LP $41
$85 — —
JAKAFI
  • Incyte Corporation $83
$83 16 —
Lenvima
  • Eisai Inc. $74
$74 — —
Doptelet
  • Sobi, Inc $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 69 with Patron

Records

451 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record